Preclinical Technology Screening

Drug solubility and bioavailability challenges are omnipresent in the pharmaceutical industry today, with over 80% of new drugs classified as poorly soluble relative to human dose requirements. Even before entering clinical evaluation stages, new therapeutics must overcome higher solubility hurdles required for concomitant non-GLP PK and initial dose range finding (DRF) studies where a linear dose-exposure relationship is required to justify further development effort and financial expenditure.